Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21383670 | 0.98 | TSHR (0.44) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL31222882 | 0.98 | TSHR (0.44) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL15238178 | 0.98 | TSHR (0.44) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL1143294 | 0.88 | TSHR (0.54) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL14052738 | 0.81 | KDM4E (0.38) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL611363 | 0.81 | CA2 (0.47) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL27924456 | 0.79 | TSHR (0.35) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL433017 | 0.79 | — | — | |
| SCHEMBL4149480 | 0.78 | USP2 (0.63) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL267542 | 0.78 | USP2 (0.63) | TSHRUSP2KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4676476-A1 | INHIBITORS OF TDP-43 AND TAU AGGREGATION | Aquinnah Pharmaceuticals, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024187126-A1 | INHIBITORS OF TDP-43 AND TAU AGGREGATION | AQUINNAH PHARMACEUTICALS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| CN-114341128-B | Bifunctional protein degradation targeting chimeric compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20240066134-A1 | mTORC1 INHIBITORS | UNIV CALIFORNIA (US) | 2024-02-29 | — | — | US | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| CN-111747944-B | Broad-spectrum anti-enveloped virus compound, composition and application thereof | 复旦大学 | 2022-09-30 | — | — | CN | disclosed |
| CN-114341128-A | Bifunctional protein degradation targeting chimera compound and preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-111747944-A | Broad-spectrum anti-enveloped virus compound, composition and application thereof | 复旦大学 | 2020-10-09 | — | — | CN | disclosed |
| EP-3318562-A2 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | Theracos Sub, LLC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20110028450-A1 | Ring-annulated dihydropyrrolo[2,1-alpha]isoquinolines | N.V. ORGANON (NL) | 2011-02-03 | — | — | US | disclosed |
| US-20110028450-A1 | Ring-annulated dihydropyrrolo[2,1-alpha]isoquinolines | N.V. ORGANON (NL) | 2011-02-03 | — | — | US | disclosed |
| EP-2152668-B1 | ORGANIC SULFUR COMPOUND AND ITS USE FOR CONTROLLING HARMFUL ARTHROPODS | SUMITOMO CHEMICAL CO (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-7838499-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-20100160434-A1 | ORGANIC SULFUR COMPOUND AND ITS USE FOR CONTROLLING HARMFUL ARTHROPOD | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-2187742-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | Theracos, Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| EP-2152668-A1 | ORGANIC SULFUR COMPOUND AND ITS USE FOR CONTROLLING HARMFUL ARTHROPOD | Sumitomo Chemical Company, Limited (JP) | 2010-02-17 | — | — | EP | disclosed |
| US-20090118201-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOSBIO, LLC | 2009-05-07 | — | — | US | disclosed |
| WO-2009026537-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2008143338-A1 | ORGANIC SULFUR COMPOUND AND ITS USE FOR CONTROLLING HARMFUL ARTHROPOD | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066134-A1 | mTORC1 INHIBITORS | MTOR, RPTOR, RICTOR | TSHR 3460/4885USP2 1983/4885KDM4E 1643/4885 |
| US-20090118201-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A4 | TSHR 4066/4885USP2 4422/4885KDM4E 1468/4885 |
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, CRKL, OSTC | TSHR 553/4885USP2 1988/4885KDM4E 1946/4885 |
| US-20110028450-A1 | Ring-annulated dihydropyrrolo[2,1-alpha]isoquinolines | CATSPER1, QDPR, NASP | TSHR 2975/4885USP2 4420/4885KDM4E 2195/4885 |
| US-20100160434-A1 | ORGANIC SULFUR COMPOUND AND ITS USE FOR CONTROLLING HARMFUL ARTHROPOD | C5, L3MBTL3, C1S | TSHR 1576/4885USP2 1418/4885KDM4E 4146/4885 |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | TSHR 3167/4885USP2 662/4885KDM4E 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.